Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Upgraded by Oppenheimer

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) was upgraded by research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The firm presently has a $4.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages […]

Related Keywords

,Inovio Pharmaceuticals Inc ,Inovio Pharmaceuticals ,Inovio Pharmaceuticals Stock Performance ,Fund Management Co ,E Fund Management Co ,Hsbc Holdings ,Nasdaq ,News Ratings For Inovio Pharmaceuticals Daily ,Group Plc ,Nuveen Asset Management ,Get Free Report ,General Group Plc ,Asset Management ,Fund Management ,Inovio Pharmaceuticals Daily ,Nasdaq Ino ,Ino ,Medical ,Upgrade ,Oppenheimer Holdings Inc ,